SAN DIEGO, July 21, 2011 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today the publication in the journal Vaccine1 of successful results from nonclinical testing of its Vaxfectin® adjuvant and Vaxfectin®-formulated plasmid DNA (pDNA) vaccines against pandemic influenza prior to their first use in human clinical trials. The results pave the path for potential future human applications of Vaxfectin® as a universal adjuvant for additional pDNA vaccines, for conventional protein-based infectious disease vaccines, and for cancer vaccines.
